ArticleCureus2025
Cutaneous Manifestation of a Rare Haematological Malignancy: A Case Report of the Presentation, Diagnosis, and Management of Blastic Plasmacytoid Dendritic Cell Neoplasm.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematological malignancy characterized by the proliferation of abnormal plasmacytoid dendritic cells. These cells infiltrate the skin and other organs during malignancy, leading to the development of violaceous skin nodules. We report a case of a middle-aged patient who presented to a secondary hospital with persistent skin lesions unresolved by primary care management and corticosteroids. A surgical excision and biopsy in secondary care revealed malignant plasmacytoid activity diffusely positive for Cluster of Differentiation (CD)4, CD123 and CD56 alongside a high Ki-67 proliferation index. A hyperfractionated cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride (Adriamycin), and dexamethasone (Hyper-CVAD) chemotherapy regimen was initiated for this patient, which resulted in a significant reduction in lesion size and an initial remission. Central nervous system (CNS) prophylaxis with intrathecal methotrexate was provided following chemotherapy to prevent CNS relapse while awaiting allogenic bone marrow transplantation. This case highlights the importance of considering BPDCN in patients with persistent or unusual skin lesions and highlights the critical role of early biopsy and immunohistochemistry in achieving an accurate diagnosis. Moreover, it emphasizes the need for a multidisciplinary team (MDT) approach to ensure optimal management and improve prognosis and patient care with this malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.